Immunocore Holdings plc (NASDAQ:IMCR) is one of the best small cap stocks to buy for the long term. Immunocore Holdings plc (NASDAQ:IMCR) announced on May 31 updated results from its Phase 1/2 trial evaluating brenetafusp in patients with heavily pretreated advanced melanoma, with the data presented in a poster at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Mohammed Dar, Chief Medical Officer of Immunocore Holdings plc (NASDAQ:IMCR), stated that the data with brenetafusp in heavily pretreated advanced melanoma exhibited “consistent responses and survival even in those with poor prognosis, including patients with primary PD-1 resistance”, adding that the data also reinforces the company’s “confidence in the potential of brenetafusp at the dose of 160 mcg in combination with nivolumab in first-line advanced melanoma, in the ongoing Phase 3 PRISM-MEL-301 trial”.
The company further reported that brenetafusp monotherapy led to a 6-month overall survival rate of 87% and disease control rate of 52% in heavily pretreated HLA-A*02:01-positive patients with melanoma, with management stating that the clinical benefit was consistent across difficult-to-treat subgroups, including patients with primary PD-1 resistance.
Immunocore Holdings plc (NASDAQ:IMCR) is a commercial-stage biotechnology company that pioneered the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease. The company’s pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
